You are here: Home :: Area NEM :: Medical science :: Human medicine

Richard C. Becker, John Alexander, Christopher K. Dyke, Robert A. Harrington

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease

The development of anticoagulants for treating patients with atherothrombotic disorders of the arterial circulatory system has focused, either directly or indirectly, on thrombin a pleuripotential effector enzyme with prothrombotic and proinflammatory properties. The pivotal role of factor (f) Xa in thrombin generation, coupled with its direct cellular effects and widely recognized limitations of currently available anticoagulants, has led to the development of pharmacologic inhibitors of this important protease. The following review focuses on DX-9065a first in a class of direct, selective and reversible fXa antagonists and its potential applications in the management of patients with cardiovascular disease.

Thrombosis and Haemostasis, Schattauer

Print ISSN: 0340-6245
Volume: 92, 12/2004
Pages: 1182 - 1193

Show full article (external site)

Show all available items of this journal

 

Area NEM